Nutra Pharma Corporation

www.nutrapharma.com

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

KANE BIOTECH ANNOUNCES NEW COLLABORATION AGREEMENTS FOR PROSTHETIC JOINT INFECTION, EXPANDING ITS DISPERSINB® APPLICATIONS

Kane Biotech Inc. | February 11, 2022

news image

Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch (UTMB) to study the use of DispersinB® with Prosthetic Joint Infection (PJI) patients. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work to be done by Josh Wenke, a Professor in the Department of O...

Read More

Cell and Gene Therapy, Industry Outlook

LIFE BIOSCIENCES AND FORGE BIOLOGICS ANNOUNCE CGMP MANUFACTURING PARTNERSHIP TO ADVANCE DEVELOPMENT OF NOVEL GENE THERAPIES FOR AGING-RELATED DISEASES

Businesswire | May 09, 2023

news image

Life Biosciences a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications. Read More

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

news image

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More

Medical

PHARMACTIVE ENTERS STRATEGIC PARTNERSHIP WITH NUTRACONNECT FOR APAC

Pharmactive | June 08, 2022

news image

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...

Read More
news image

Industrial Impact

KANE BIOTECH ANNOUNCES NEW COLLABORATION AGREEMENTS FOR PROSTHETIC JOINT INFECTION, EXPANDING ITS DISPERSINB® APPLICATIONS

Kane Biotech Inc. | February 11, 2022

Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch (UTMB) to study the use of DispersinB® with Prosthetic Joint Infection (PJI) patients. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work to be done by Josh Wenke, a Professor in the Department of O...

Read More
news image

Cell and Gene Therapy, Industry Outlook

LIFE BIOSCIENCES AND FORGE BIOLOGICS ANNOUNCE CGMP MANUFACTURING PARTNERSHIP TO ADVANCE DEVELOPMENT OF NOVEL GENE THERAPIES FOR AGING-RELATED DISEASES

Businesswire | May 09, 2023

Life Biosciences a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications. Read More

news image

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More
news image

Medical

PHARMACTIVE ENTERS STRATEGIC PARTNERSHIP WITH NUTRACONNECT FOR APAC

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engin...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us